EQT Life Sciences and Gimv Co-Lead €51 Million Series B for Exciva’s Alzheimer’s Therapy
EQT Life Sciences and Gimv have co-led a €51 million Series B funding round for Exciva to advance its lead candidate, Deraphan, into Phase 2 clinical trials targeting agitation in Alzheimer’s disease.